Thymosin Alpha 1 Significantly Reduces Mortality in Critical COVID-19 Patients

The COVID-19 pandemic presented an unprecedented global health crisis, with a significant proportion of patients developing critical illness characterized by severe pneumonia, acute respiratory distress syndrome (ARDS), and a dysregulated immune response often leading to a cytokine storm. Effective immunomodulatory therapies were urgently needed to improve outcomes in these severely affected individuals. While thymosin α1 (Tα1), a naturally occurring immunomodulatory peptide, has known roles in enhancing T-cell function and modulating cytokine production, its specific impact on mortality in critically ill COVID-19 patients was not well-established.

The study revealed a statistically significant reduction in mortality among patients treated with thymosin α1. The 28-day all-cause mortality in the Tα1 group was 24.8% (41/165), compared to 39.5% (64/162) in the control group, representing a 14.7% absolute reduction in mortality (p<0.001). Patients receiving thymosin α1 demonstrated a 43% lower risk of death (Adjusted Hazard Ratio: 0.57, 95% CI: 0.39-0.83, p=0.003) compared to controls, after adjusting for confounding factors. Furthermore, the Tα1 group showed significantly improved lymphocyte counts and reduced levels of inflammatory markers such as C-reactive protein and interleukin-6 (p<0.05 for all), suggesting a beneficial immunomodulatory effect. The median length of ICU stay was also numerically shorter in the Tα1 group (12 days vs. 16 days), although this difference did not reach statistical significance (p=0.06).